Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.
Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.